Home / Stocks / LMAT

Lemaitre Vascular (LMAT, Health Care Equipment) Stock Valuation & Fair Value Significantly overvalued

Lemaitre Vascular (LMAT, Health Care Equipment) trades at a blended P/E of 28.4, about 26% below its historical normal valuation, with a forward growth estimate of 10.1% and a PEG of 2.82. Analysts' one-year estimates have been hit 27% of the time. Priced at its historical normal P/E of 38.4 on the same blended earnings, the 2026-09-18 close of $78.87 corresponds to about $107 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
28.4
Normal P/E
38.4
PEG
2.82
Fwd growth
10.1%
Div yield
1.3%
RSI (14)
45.7
Neutral
Technical context
  • Price $80.58 at the 2026-09-23 close, 0.7% above the 20-day average ($80.04) and 7.4% below the 50-day ($87.03).
  • RSI (14) at 45.7.
  • 52-week range $78.76 to $116.75: the price is 31.0% below the high and 2.3% above the low.

The Street vs SeerForecast

Wall Street's mean price target for LMAT is $107.00 across 7 analysts, 32.8% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 36.5 to 28.4 between 2026-07-31 and 2026-09-21, against a normal P/E of 38.4, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 36.5, Significantly overvalued (recalculated)2026-08-03: P/E 36.2, Significantly overvalued2026-08-07: P/E 36.2, Significantly overvalued (recalculated)2026-08-10: P/E 29.7, Significantly overvalued2026-08-14: P/E 29.7, Significantly overvalued (recalculated)2026-08-17: P/E 30.0, Significantly overvalued2026-08-21: P/E 30.0, Significantly overvalued (recalculated)2026-08-24: P/E 29.8, Significantly overvalued2026-08-27: P/E 29.8, Significantly overvalued (recalculated)2026-08-28: P/E 29.8, Significantly overvalued (recalculated)2026-08-30: P/E 29.8, Significantly overvalued (recalculated)2026-08-31: P/E 29.2, Significantly overvalued2026-09-05: P/E 29.2, Significantly overvalued (recalculated)2026-09-07: P/E 29.2, Significantly overvalued2026-09-12: P/E 29.2, Significantly overvalued (recalculated)2026-09-14: P/E 29.1, Significantly overvalued2026-09-19: P/E 29.1, Significantly overvalued (recalculated)2026-09-21: P/E 28.4, Significantly overvalued30.035.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 38.4
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 36.5-5%Significantly overvalued
2026-09-21P/E 28.4-26%Significantly overvalued ← now

Frequently asked questions

Is Lemaitre Vascular stock overvalued?

At a blended P/E of 28.4 versus its historical normal P/E of 38.4, Lemaitre Vascular trades about 26% below its typical valuation, with a PEG of 2.82 on 10.1% forward growth. tickerseer currently rates it significantly overvalued.

What is Lemaitre Vascular's fair value and PEG?

Lemaitre Vascular trades at a blended P/E of 28.4 against a historical normal P/E of 38.4, a PEG of 2.82, and a forward growth estimate of 10.1%. Priced at its historical normal P/E of 38.4 on the same blended earnings, the 2026-09-18 close of $78.87 corresponds to about $107 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of Lemaitre Vascular changed?

tickerseer's rating has been significantly overvalued since 2026-07-31.

What is the analyst price target for Lemaitre Vascular?

The mean Wall Street price target for Lemaitre Vascular is $107.00 across 7 analysts, 32.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Equipment. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track LMAT free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.